Sign in
Taking people in United StatesPhase 2

Tests radiotherapy with immunotherapy before surgery for rare mucosal melanoma

Tests radiation before surgery, after immunotherapy, in adults with sinonasal or anorectal melanoma.

Key facts

Who runs it
M.D. Anderson Cancer Center
Where
Houston, United StatesSee the site
Trial code
Registry title
Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma
Status
Recruiting
Phase
Phase 2
People taking part
40 people, planned
Started
31 Oct 2022
Expected to end
31 Jul 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Surgical resection
Record updated
10 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with melanoma of the nasal cavity or sinuses, or of the anorectal canal, with no spread to distant parts of the body. They are planned for combination immunotherapy.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Melanoma in the nasal cavity or paranasal sinuses (Arm 1), or in the anorectal canal (Arm 2). A tumor must be seen on exam or imaging. No distant metastasis. ECOG performance status of 3 or lower.
Earlier treatment
Must be planned for combination immunotherapy (for example ipilimumab and nivolumab, or nivolumab and relatlimab). No previous radiation to the planned treatment area.

Main reasons for not taking part

  • Metastatic disease
  • Previous radiation therapy to the planned target area
  • Pregnancy
  • Under 18 years of age

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • For all patients
  • Evidence of mucosal tumor on clinical exam or imaging
  • No evidence of distant metastasis
  • Patients must be planned for combination immunotherapy (e.g. ipilimumab and nivolumab or nivolumab and relatlimab)
  • ECOG performance status ≤3
  • Age ≥18 years because melanoma is extremely rare in patients <18 years of age and RT is considered high risk in this population due to risk of secondary malignancy and potentially growing tissues that may be adversely impacted by RT
  • RT is a known teratogen. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (refer to MDA Policy CLN 1114) This includes all female patients, between the onset of menses and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:
  • Postmenopausal (no menses in greater than or equal to 12 consecutive months)
  • History of hysterectomy or bilateral salpingo-oophorectomy
  • Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy)
  • History of bilateral tubal ligation or another surgical sterilization procedure. Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of RT
  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with their ability to safely receive the study interventions are eligible for this trial
  • Ability to understand and the willingness to sign a written informed consent document; For Arm 1 patients (sinonasal melanoma)
  • Patients must have histologically or cytologically confirmed melanoma involving the nasal cavity and/or paranasal sinuses
  • Patients must be evaluated by Head and Neck Surgery to establish surgical status as resectable, borderline resectable or unresectable
  • Patients must have a baseline skull base MRI unless contraindicated by medical or financial toxicity; For Arm 2 patients (anorectal melanoma)
  • Patients must have histologically or cytologically confirmed melanoma involving the anorectal canal
  • Patients must be evaluated by the surgical team to establish primary tumor surgical status as: (1) resectable with sphincter sparing approach, (2) resectable with abdominoperineal resection, or (3) unresectable/requiring surgery greater than abdominoperineal resection
  • Patients must have a baseline rectal MRI unless contraindicated by medical or financial toxicity; 2.2 Exclusion Criteria
  • Previous radiation therapy to the planned target area (sinonasal for Arm 1 and anorectal for Arm 2)
  • Metastatic disease
  • Pregnant women are excluded from this study because RT is a known teratogen
  • Patients who are less than 18 years of age because melanoma is extremely rare in this population and the treatment agent is a known carcinogen

Where in United States

  • M D Anderson Cancer CenterHouston, United StatesContact: Devarati MitraTaking people

About the trial

What the trial wants to find out

The goal of this clinical research study is to learn if pre-operative radiation therapy after starting immune checkpoint inhibition can help patients with sinonasal or anorectal melanoma have better outcomes

The 2 groups in the trial

  • Sinonasal melanoma: patients with sinonasal melanomaTreatment being tested

    A. Patients with upfront resectable disease Treatment: * Immunotherapy * 20 fraction radiation therapy +/- ongoing immunotherapy * Surgery B. Patients whose disease is not resectable at presentation Treatment: Immunotherapy with potential to enter resectable disease pathway if tumor becomes resectable or continue treatment as per multidisciplinary team preference if tumor does not become resectable

    Treatment: Surgical resection

  • Anorectal melanoma: patients with anorectal melanomaTreatment being tested

    A. Patients with disease resectable with a sphincter sparing procedure Treatment: * Immunotherapy * 5 fraction radiation therapy * Surgery B. Patients with disease not resectable with a sphincter sparing procedure Treatment: * Immunotherapy to maximal response * 5 or 15 fraction radiation (depending on immunotherapy response) +/- ongoing immunotherapy * Surgery or biopsy

    Treatment: Surgical resection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma
Plain-language title
Tests radiotherapy with immunotherapy before surgery for rare mucosal melanomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
10 September 2026